Poster Abstract Session:
059. Hepatitis B and C in Varied Settings
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Tracks: Adult ID, Epidemiology and Infection Control, Global ID, Pediatric ID


Presentations:
513
Hepatitis C Testing Strategies in a Correctional Setting
Sabrina A. Assoumou, MD, MPH; Jianing Wang, MSc; Abriana Tasillo, BA; Golnaz Eftekhari Yazdi, MSc; Judith I. Tsui, MD MPH; Susan H. Hariri, PhD; Claudia J. Vellozzi, MD, MPH; Lara Strick, MD MS; Benjamin P. Linas, MD, MPH
514
High Incidence of Hepatitis C Virus (HCV) Infection among an Urban Emergency Department (ED) Patients. 2003 – 2016.
Anuj Patel, MD; Richard Rothman, MD, PhD; David Thomas, MD, MPH, FIDSA; Yu-Hsiang Hsieh, PhD
515
Where is the US Hepatitis C Epidemic *Now*? Putting the "Pen" on the Map as Elimination Efforts Hunt for Remaining Cases.
Cesar A Taborda Vidarte, MD; Emeli J Anderson, MSPH; Mohammed A Khan, MSPH; Jennifer A Phillips, MPH; Anne C Spaulding, MD, MPH, FIDSA
516
African-Born Status and Risk of Hepatocellular Carcinoma among Patients with Chronic Hepatitis B Infection
Kaitlyn Kennedy, BA; Nayan Arora, MD; Susan Graham, MD; MPH; PhD; H. Nina Kim, MD, MSc
Posters
  • AfricanHCChepB.pdf (457.2 kB)
  • 518
    APRI Score as A predictor of Significant Liver Fibrosis In Chronic Hepatitis B
    Houda Ben Ayed, MD; Makram Koubaa, MD; Sourour Yaich, MD; Yosra Mejdoub, MD; Fatma Smaoui, MD; Tarak Ben Jemaa, MD; Imed Maaloul, MD; Chakib Marrakchi, MD; Jamel Dammak, MD; Mounir Ben Jemaa, MD
    519
    Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir / Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
    Adeel Butt, MD, MS; Yanjie Ren, MS; Amy Puenpatom, PhD; Jean Marie Arduino, ScD, MS; Ritesh Kumar, PhD; Abdul-Badi Abou-Samra, MD, PhD
    520
    Factors associated with appropriate hepatocellular carcinoma (HCC) screening among chronic hepatitis C (HCV) patients with cirrhosis at an urban safety-net hospital system
    Nicolo Cabrera, MD; Kerianne Burke, MPH; Gregory Huhn, MD, MPH; Benjamin Go, MD; Crystal Winston, BA; Oluwatoyin Adeyemi, MD
    Posters
  • IDWeek 2017 poster.JPG (2.4 MB)
  • 521
    Patterns of Testing in Children Exposed Perinatally Exposed to Hepatitis C
    Claudia Espinosa, MD, MSc; John Myers, PhD; Michael Smith, Smith
    524
    Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population
    Julia Marcus, PhD, MPH; Leo Hurley, MPH; Scott Chamberland, PharmD; Jamila Champsi, MD; Laura Gittleman, RN, MBA; Daniel Korn, MD; Jennifer Lai, MSc, PharmD; Charles Quesenberry Jr., PhD; Joanna Ready, MD; Varun Saxena, MD; Suk Seo, MD; David Witt, MD; Michael Silverberg, PhD, MPH
    525
    Making the Case for Universal Screening of Pregnant Women for Hepatitis C Virus: One State at a Time
    Annie Morse, H.S.; A. Sid Barritt IV, M.D., MSCR; Ravi Jhaveri, MD, FIDSA, FPIDS
    526
    Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES
    Adeel Butt, MD, MS; Peng Yan, MS; Obaid Shaikh, MD; Abdul-Badi Abou-Samra, MD, PhD
    527
    Mental Health, Heart Disease, and Lack of Insurance Associated with Not Receiving Hepatitis C Treatment in Safety-Net Hospitals
    Mamta K Jain, MD, MPH; Robert Wong, MD; Onkar Kshirsagar, MS; Christopher Clark, MPA; Mae Thamer, PhD
    Posters
  • PosterIDSA2017 10.9.17.pdf (558.6 kB)
  • 528
    HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
    Adeel Butt, MD, MS; Yanjie Ren, MS; Amy Puenpatom, PhD; Jean Marie Arduino, ScD, MS; Ritesh Kumar, PhD; Abdul-Badi Abou-Samra, MD, PhD
    529
    Evaluation of the Hepatitis C Cascade of Care in a Multidisciplinary Infectious Diseases Clinic
    Autumn Zuckerman, PharmD, BCPS, AAHIVP; Andrew Douglas, MPH; Cody Chastain, MD
    531
    Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey
    Julia Kang Cornett, MD; Vimal Bodiwala, MD; Victor Razuk, BS; Devangi Shukla, BS, MBS; Navaneeth Narayanan, Pharm D, BCPS
    534
    Use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
    Minas Economides, M.D.; Jeff Hosry, M.D.; Georgios Angelidakis, M.D.; Ahmed Kaseb, MD; Harrys Torres, M.D.
    535
    Effectiveness of 8 or 12 Week Treatment Duration of Ledipasvir/Sofosbuvir for Hepatitis C: Evidence from a Large Academic Medical Center
    Ana Vega, PharmD; Lauren Hynicka, PharmD, BCPS; Kimberly Claeys, PharmD, BCPS; Emily Heil, PharmD, BCPS-AQID
    537
    Telehealth for Hepatitis C care in the DAA era; ensuring everyone can access a cure
    Thomas Ray Schulz, MBBS, BSc, FRACP; Kudzai Kanhutu, FRACP; Joe Sasadeusz, PhD, FRACP; Sally Watkinson, Registered Nurse; Beverley Ann Biggs, PhD, FRACP
    539
    Barriers to Successful Linkage to Care Among HCV Positive Individuals Presenting to a Major Tertiary Medical Center on Long Island, New York.
    Audun Lier, MD, MPH; Kerim Odekon, MD; Ruth Abeles, MD, MS; Silvia Bronson, MS; Jacqueline Colon, MHA; Inderjit Mann, MD; Lily Coyle, BS; Kalie Smith, BS; Bettina C. Fries, MD, FIDSA; Luis A. Marcos, MD, MPH
    Posters
  • Lier_Audun_HCV_IDSA2017.pdf (546.7 kB)
  • 540
    Implementation of a Comprehensive Hepatitis C Virus (HCV) Treatment Program in Metro-Detroit
    Reda Awali, MD, MPH; Prateek Lohia, MD; Jennifer Veltman, MD; Jonathan Cohn, MD, MS, FIDSA; Lawrence R Crane, MD, FACP, FIDSA
    Posters
  • Awali_WSU_HCV.pdf (1.3 MB)
  • 541
    Improving Hepatitis C Screening Rates in Primary Care
    Saira Ajmal, MD; Anil Jagtiani, M.D.; Matthew Thoendel, MD, PhD; Maryam Mahmood, MD; Rajeev Chaudhry, MBBS, MPH; Andrew Franqueira, Acting Lead Analyst/Programmer; Jennifer Whitaker, MD, MS
    Posters
  • idsa poster final sep 27.pdf (671.9 kB)
  • 542
    Impact of Insurance and Treatment Regimens on HCV Outcome: Longterm follow up study
    Mallikarjuna Mukka, MD; Sami Akram, MD; Janak Koirala, MD, FIDSA
    Posters
  • HCV IDWeek POSTER MUKKA.pdf (867.1 kB)
  • 544
    Retreatment of chronic HCV infection after second generation DAA failure in patients in the NJ VA Healthcare System
    Kimberly Stawarz, MD; Clinton Kaminski, PA-C; Sandra Kaminski, MS, PA-C; Alexandra Sonyey, MD
    Posters
  • IDSA 2017 hepC poster.pdf (478.9 kB)
  • 545
    Assessing gaps in Hepatitis C Care in Primary Care.
    Anais Ovalle, MD; Paulette Pinargote, MD; Osama Siddique, MD; Valeria Fabre, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.